Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss drug.

Jason Betz, private wealth advisor at Redwood Wealth Advisors, Ameriprise Financial, said that if President Trump's tariffs ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns about signs of weakness in sales of its popular diabetes and weight-loss ...